$CWCO

Consolidated Water Secures $39.8M Design-Build for Central Coast Blue With Pismo Beach

Consolidated Water's subsidiary, PERC Water, secured a $39.8M fixed-price contract with the City of Pismo Beach to build the Central Coast Blue Advanced Water Purification Facility. The project, expected to complete by September 2028, includes design, construction, and training, with penalties for delays. The facility will initially produce 500 acre-feet of water annually, with potential future expansion.

Original reporting
Published Oct 15, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Consolidated Water Secures $39.8M Design-Build for Central Coast Blue With Pismo Beach — source image
Decision brief

The 30-second read

$CWCONeutralLow
01

Why it matters

The $39.8 M contract adds a new revenue source and may improve the company's order backlog, but the modest size limits immediate price impact.

02

Market read

A new mid‑size contract for a water‑purification plant provides incremental upside for CWCO but is unlikely to drive a large price move.

03

What to watch

Potential for future expansion phases or additional contracts with the city could amplify the long‑term impact.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Consolidated Water (CWCO) is a water‑services company that provides treatment and infrastructure solutions. The firm filed an 8‑K on Oct 15 2026 announcing the new design‑build agreement.

Company-level read

Ticker impact

$CWCONeutralMedium confidence
Context

Consolidated Water announced a $39.8 million fixed‑price design‑build contract for a new water‑purification plant in California.

Expected impact

likely modest upside pressure as investors price in the new revenue stream

Evidence & confidence

A single $40 M contract is material for a mid‑cap water services firm, but it does not represent a transformative shift.

Market effects

May signal continued demand for water‑infrastructure projects in California, modestly supporting the water services sector.

Limited to California utilities and construction markets.

Low; the contract is regional and does not affect broader global markets.

Counterpoint

The contract size is too small to move the stock significantly; investors may already have priced it in.

Key entities

  • Consolidated Water Co. Ltd.

    US‑listed water‑services provider (ticker CWCO).

  • City of Pismo Beach

    Contracting authority for the water‑purification facility.

Related articles

$CWCOMed

Consolidated Water (CWCO) Q2 2026 Earnings Call Transcript

Consolidated Water (CWCO) reported Q2 2026 revenue of $32.9M, down 2% YoY, driven by a 49% drop in manufacturing revenue. Net income from continuing operations was $4.0M, or $0.25 diluted EPS, vs $5.2M, or $0.32. Cash was $132.6M at June 30, 2026. The company cited permitting delays in Hawaii and growth in bulk and services.

$CWCOMed

Consolidated Water Q2 Earnings Call Highlights

Consolidated Water (NASDAQ:CWCO) reported Q2 services revenue up 1% to $11.6M, helped by construction work in Colorado and California, partly offset by lower O&M after two customer contracts expired. Manufacturing revenue fell 49% to $2.7M. Gross profit was $11.0M (33% of revenue). The company received a 25-year Grand Cayman license, and noted Hawaii desalination and Florida equipment orders.

$CWCOMed

Consolidated Water Reports Second Quarter 2026 Results

Consolidated Water Co. Ltd. (CWCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Consolidated Water Reports Second Quarter 2026 Results ​ GEORGE TOWN, Grand Cayman, Cayman Islands, August 10, 2026 -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, re

$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

$MLYSMedAI 8/10

Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease

Mineralys Therapeutics (MLYS) reported Phase 2 trial results for Lorundrostat in chronic kidney disease patients, showing significant blood pressure reduction and kidney damage markers improvement. The drug is being evaluated for high blood pressure and related conditions. MLYS stock is currently at $21.09, down 0.21%.